← Human Trials & Peer-Reviewed Studies
Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity
Plain-language guide to PMID 23462665 (2013): double-blind randomized controlled trial study of Exenatide.
Key Facts
- PMID
- 23462665
- Journal
- Diabetes care
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Schlögl H et al. (11 authors)
- DOI
- 10.2337/dc12-1925
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Exenatide.
Why only some individuals respond with weight loss and others do not remains unclear.
Who Took Part
The age groups tagged for this paper are young adults and adults, men only.
The researchers performed a randomized, double-blinded, placebo-controlled, cross-over fMRI study with intravenous administration of exenatide in obese male volunteers.
During brain scanning with continuous exenatide or placebo administration, participants rated food and nonfood images.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The participants were allocated by chance, so the Exenatide group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.
In the crossover set-up each of the participants took both Exenatide and the comparison in turn, acting as their own control.
After each scanning session, energy intake was measured using an ad libitum buffet.
Functional hypothalamic connectivity was assessed by eigenvector centrality mapping, a measure of connectedness throughout the brain.
What Was Measured
The subject headings attached to it are Algorithms, Blood Glucose, Energy Intake, Exenatide, Hypothalamus, Insulin and Magnetic Resonance Imaging.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exenatide.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2013 (Diabetes care), a journal based in United States.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.